Form 8-K Dare Bioscience, Inc. For: Jul 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Dare Bioscience faces Nasdaq delisting over equity deficiency
July 17, 2026 4:10 PM EDTDare Biosciences, Inc. (NASDAQ: DARE) received a notification from Nasdaq's Listing Qualifications Staff on July 13, 2026, stating that the company no longer complies with Nasdaq Listing Rule 5550(b).
According to the company's Form 10-Q for the period ended March 31, 2026, stockholders' equity fell below the required... More
